Conestoga Capital Advisors LLC Makes New $43.04 Million Investment in Artivion, Inc. $AORT

Conestoga Capital Advisors LLC bought a new stake in shares of Artivion, Inc. (NYSE:AORT) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 1,175,410 shares of the company’s stock, valued at approximately $43,044,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Summit Partners Public Asset Management LLC bought a new position in Artivion in the fourth quarter worth approximately $39,401,000. Invesco Ltd. grew its position in shares of Artivion by 211.9% during the 4th quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock valued at $50,228,000 after acquiring an additional 748,119 shares during the period. Champlain Investment Partners LLC bought a new stake in shares of Artivion during the 3rd quarter valued at $17,912,000. Goldman Sachs Group Inc. increased its stake in shares of Artivion by 144.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 537,375 shares of the company’s stock worth $24,510,000 after purchasing an additional 317,518 shares in the last quarter. Finally, Two Sigma Investments LP increased its stake in shares of Artivion by 235.5% in the 3rd quarter. Two Sigma Investments LP now owns 446,535 shares of the company’s stock worth $18,906,000 after purchasing an additional 313,446 shares in the last quarter. 86.37% of the stock is owned by institutional investors.

Artivion Stock Performance

NYSE:AORT opened at $23.60 on Thursday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.80 and a current ratio of 3.86. The stock’s fifty day moving average is $25.11 and its 200 day moving average is $34.82. The firm has a market capitalization of $1.15 billion, a PE ratio of 98.34 and a beta of 1.26. Artivion, Inc. has a fifty-two week low of $19.16 and a fifty-two week high of $48.25.

Insider Buying and Selling at Artivion

In other news, SVP Andrew M. Green sold 44,001 shares of the firm’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $20.70, for a total value of $910,820.70. Following the completion of the sale, the senior vice president owned 60,259 shares in the company, valued at approximately $1,247,361.30. This trade represents a 42.20% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.30% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Needham & Company LLC decreased their price objective on shares of Artivion from $58.00 to $44.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. Wall Street Zen lowered Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Weiss Ratings lowered Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, June 8th. Canaccord Genuity Group restated a “buy” rating and issued a $36.00 price objective on shares of Artivion in a research report on Tuesday, June 16th. Finally, LADENBURG THALM/SH SH upgraded Artivion from a “neutral” rating to a “buy” rating and set a $42.00 target price for the company in a research report on Friday, April 10th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $44.17.

Artivion Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.